Sofie Biosciences unveils preclinical PET unit

Sofie Biosciences has launched a preclinical PET unit that facilities can use to identify and evaluate new cancer and inflammation probes.

The Culver City, Calif.-based company touts the device as a low-cost imaging system capable of organ-level tissue quantification.

The firm said the system has "significant value in being able to rapidly label a small molecule or biological and carry out a low-cost high-sensitivity biodistribution assay, prior to imaging with a high resolution PET or PET/CT system."

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.